How to Get Zepbound in Arizona

What Zepbound Is and Why Arizona Residents Are Seeking It

Zepbound is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Demand in Arizona has accelerated sharply since approval, partly because the state's adult obesity rate reached 31.5% according to CDC Behavioral Risk Factor Surveillance System data [1].

What the Clinical Data Show

The SURMOUNT-1 trial (N=2,539, published in the New England Journal of Medicine, 2022) remains the definitive efficacy dataset for tirzepatide in weight management. Participants receiving tirzepatide 15 mg lost a mean of 20.9% of body weight at 72 weeks, compared with 3.1% in the placebo group (P<0.001) [2]. The 10 mg dose produced 19.5% mean weight loss. Those numbers are higher than any previously approved weight-management drug.

SURMOUNT-2 (N=938) extended those findings to adults with type 2 diabetes, reporting 15.7% mean weight loss at 72 weeks on tirzepatide 15 mg versus 3.3% on placebo [3]. Together, these trials formed the core of Eli Lilly's FDA submission package.

The Difference Between Zepbound and Mounjaro

Tirzepatide is sold under two brand names. Mounjaro carries an indication for type 2 diabetes. Zepbound carries the obesity/weight-management indication. The active molecule is identical, the doses are identical, and the injection devices are identical. Insurance routing is the meaningful difference: a claim for obesity management must reference Zepbound, not Mounjaro, or it will be rejected for the wrong indication.

Arizona Telehealth Rules for Zepbound Prescriptions

Telehealth prescribing for Zepbound is fully legal in Arizona. The state adopted the Interstate Medical Licensure Compact and aligned its telehealth statute (A.R.S. §36-3602) with federal Ryan Haight Act requirements, meaning a prescriber must hold an Arizona license and conduct a proper medical evaluation before issuing a controlled substance or, in the case of tirzepatide, a Schedule-uncontrolled prescription drug.

What a Telehealth Visit for Zepbound Looks Like

A qualifying telehealth visit is not a rubber stamp. The clinician reviews your weight history, current BMI, relevant comorbidities (hypertension, dyslipidemia, sleep apnea, type 2 diabetes, or cardiovascular disease), current medications, and contraindications. Contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, because GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumors in rodents [4].

The visit typically runs 20 to 40 minutes by video. A small number of platforms use asynchronous questionnaires, though asynchronous-only visits carry regulatory risk in Arizona and are not recommended.

Which Providers Can Prescribe in Arizona

Arizona law allows the following license types to prescribe Zepbound independently or with supervision:

• Medical Doctors (MD) and Doctors of Osteopathic Medicine (DO): full independent prescribing authority.
• Nurse Practitioners (NP): Arizona statute A.R.S. §32-1606 grants NPs independent prescribing authority, meaning no supervising physician is required.
• Physician Assistants (PA): PAs in Arizona may prescribe under a supervising physician agreement.

Naturopathic Doctors (ND) licensed in Arizona may prescribe a limited formulary; tirzepatide is not currently on that formulary, so an ND cannot prescribe Zepbound.

Required Labs Before and During Zepbound Treatment in Arizona

No Arizona statute mandates a specific lab panel before tirzepatide initiation, but the Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends baseline metabolic screening to rule out secondary causes of weight gain and to establish a safety baseline [5].

Recommended Baseline Labs

Most Arizona prescribers and telehealth platforms order a standard panel that includes:

• HbA1c and fasting glucose (to assess pre-diabetes or diabetes status)
• Comprehensive metabolic panel (CMP) for renal and hepatic function
• Lipid panel
• TSH (thyroid-stimulating hormone) to screen for hypothyroidism
• CBC (complete blood count)

Some clinicians add a lipase level, because tirzepatide has been associated with pancreatitis, though causality in humans remains under investigation. A urine pregnancy test is standard for people of childbearing potential; Zepbound is not recommended during pregnancy.

Ongoing Monitoring

After initiation, most protocols recheck HbA1c and CMP at three months and at six months. Weight and blood pressure are tracked at every visit. If a patient develops persistent severe abdominal pain, the prescriber should suspend tirzepatide and check lipase and amylase immediately.

How to Get a Zepbound Prescription in Arizona: Step-by-Step

The process from decision to first dose generally follows this sequence.

Step 1: Confirm You Meet the FDA Label Criteria

The FDA-approved indication requires a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity. If you fall below 27 kg/m², no licensed prescriber in Arizona can write a medically appropriate on-label prescription.

Step 2: Choose In-Person or Telehealth

Both pathways are valid. In-person visits are available at obesity medicine specialists, endocrinologists, primary care physicians, and weight-loss clinics across Phoenix, Tucson, Scottsdale, Mesa, and Chandler. Telehealth visits are available through multiple national and Arizona-based platforms. HealthRX connects Arizona patients with licensed physicians who specialize in GLP-1 therapy, and initial visits can be completed by video within 48 hours of booking.

Step 3: Complete the Medical Evaluation and Labs

Order labs before your appointment if the platform allows it, so the prescriber has results in hand during the visit. Major draw sites such as Quest Diagnostics and Labcorp have over 60 locations across the Phoenix metro and more than 20 in Tucson. Results typically return within one to three business days.

Step 4: Receive the Prescription and Manage Insurance

If you have commercial insurance, the prescriber or their staff submits a prior authorization (PA) request. If you are uninsured or on AHCCCS (Arizona Medicaid), you will pay out of pocket, because AHCCCS does not cover Zepbound for chronic weight management.

Step 5: Pick Up or Receive Your Medication

The prescription routes to your chosen pharmacy. Brand-name Zepbound, dispensed through Eli Lilly's LillyDirect program or a retail/specialty pharmacy, arrives in the auto-injector pen format. Patients using 503A compounding pharmacies receive a vial-and-syringe format instead.

Insurance Coverage and Prior Authorization in Arizona

Prior authorization for Zepbound is required by most Arizona commercial insurers. The documentation package typically needs to include:

• A confirmed BMI measurement from a clinical visit (not self-reported)
• Documentation of at least one weight-related comorbidity if BMI is 27 to 29.9 kg/m²
• Evidence of a prior structured weight-management program (usually three to six months of diet and exercise counseling, though requirements vary by plan)
• The prescriber's clinical notes establishing medical necessity

What Arizona Medicaid Does and Does Not Cover

AHCCCS, the Arizona Medicaid program, does not cover Zepbound or any GLP-1 agonist for the obesity indication as of early 2025. Mounjaro may be covered for members with a type 2 diabetes diagnosis under the diabetes indication. The American Diabetes Association Standards of Care 2024 support GLP-1 and dual GIP/GLP-1 agonists as preferred agents in type 2 diabetes when cardiovascular disease risk is high, which could support a Mounjaro PA for qualifying AHCCCS members [6].

Appealing a Denial

Arizona law (A.R.S. §20-2537) gives plan members the right to an internal appeal and then an independent external review. A prescriber's letter of medical necessity, paired with SURMOUNT-1 efficacy data and the patient's documented comorbidities, is the strongest appeal package. The Obesity Medicine Association notes that appeal success rates improve when letters cite peer-reviewed outcomes data directly [7].

Zepbound Pharmacy Access in Arizona

Brand-Name Zepbound at Retail and Specialty Pharmacies

Brand-name Zepbound is a specialty medication. CVS Specialty, Walgreens Specialty, and Kroger/Fry's specialty departments in Arizona stock it, though local retail availability fluctuates. The LillyDirect program ships directly to Arizona patients for $550 per month out of pocket (1.25 mg through 15 mg doses) for those without insurance coverage, with a Lilly savings card available for commercially insured patients that can reduce cost to $25 per month for eligible plans [8].

503A Compounding Pharmacies in Arizona

Arizona-licensed 503A compounding pharmacies may legally prepare tirzepatide for individual patients on the basis of a valid prescription. The FDA removed tirzepatide from its shortage list for certain concentrations in late 2024, which added complexity to the 503A dispensing picture. Prescribers should verify the current shortage designation at the FDA drug shortage database before routing a patient to a 503A compounder, because 503A pharmacies may only compound drugs that appear on the shortage list or that meet other statutory criteria under Section 503A of the Federal Food, Drug, and Cosmetic Act [9].

Compound tirzepatide typically costs $200 to $400 per month for a maintenance dose, substantially below brand-name pricing. The trade-off is that compound products lack the FDA's manufacturing oversight, and potency verification depends on the individual pharmacy's quality controls.

Transferring a Prescription to Arizona

If you have an existing Zepbound prescription from another state and relocate to or visit Arizona, a retail pharmacy in Arizona can fill it provided the original prescriber holds a DEA registration and the prescription was issued lawfully. Since tirzepatide is not a controlled substance, transfer is straightforward under standard pharmacy practice rules. A 503A compounding pharmacy in Arizona requires a new Arizona-issued prescription from a licensed Arizona provider.

Zepbound Dosing Schedule Arizona Prescribers Follow

Zepbound follows a structured dose-escalation protocol designed to minimize gastrointestinal side effects. The starting dose is 2.5 mg subcutaneously once weekly for four weeks. The dose then increases by 2.5 mg increments every four weeks, targeting 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Most patients reach a maintenance dose of 10 mg or 15 mg, though some tolerate and remain at 5 mg or 7.5 mg if side effects limit escalation.

The SURMOUNT-1 protocol used exactly this titration schedule. Gastrointestinal adverse events (nausea, diarrhea, vomiting) occurred in 44% of participants at 15 mg but were predominantly mild to moderate and transient, concentrated in the first eight weeks [2].

Injection Technique

Each Zepbound auto-injector is single-use. Injection sites rotate among the abdomen, thigh, and upper arm. The abdomen is preferred for most patients because absorption is consistent. Injections go into subcutaneous fat, not muscle. Arizona patients receiving 503A compound tirzepatide use a vial and a standard 1 mL insulin syringe, typically drawing the prescribed volume and injecting subcutaneously with a 29 to 31 gauge needle.

Managing Side Effects

The most effective strategy for nausea is eating smaller portions and avoiding high-fat meals on injection day. Ginger tea or over-the-counter ondansetron (if prescribed) can reduce nausea acutely. Constipation, the second most common complaint, responds to increased hydration, dietary fiber, and, if needed, polyethylene glycol 3350. Prescribers in Arizona generally advise patients to stay at the current dose for an extra four weeks rather than escalating if side effects remain bothersome.

Special Populations and Considerations in Arizona

Age and Pediatric Use

Zepbound is FDA-approved for adults aged 18 and older. Pediatric use of tirzepatide for obesity has not yet received FDA approval, though trials are ongoing. Arizona providers should not prescribe Zepbound off-label for patients under 18.

Zepbound During Pregnancy and Breastfeeding

The FDA label states that Zepbound should be discontinued at least two months before a planned pregnancy. Animal studies showed fetal harm at doses producing exposures similar to human therapeutic doses. No adequate human data exist. Breastfeeding is a contraindication because tirzepatide excretion in human milk is unknown.

Patients with Type 2 Diabetes in Arizona

Tirzepatide lowers blood glucose substantially. Arizona patients on sulfonylureas or insulin who start Zepbound may need dose reductions in those agents to avoid hypoglycemia. Coordination between the Zepbound prescriber and the diabetes care team is necessary and represents the standard of care per the 2024 ADA Standards of Medical Care in Diabetes [6].

How HealthRX Connects Arizona Patients with Zepbound Prescribers

HealthRX operates a network of board-certified physicians and licensed nurse practitioners who hold active Arizona medical licenses. An initial video consultation can be completed within 48 hours. Lab order coordination, prescription routing, and pharmacy selection assistance are included in the consultation fee. For patients pursuing brand-name Zepbound, the HealthRX clinical team submits prior authorization requests on the patient's behalf and tracks appeal timelines.

Dr. Sarah Mendez, MD, ABOM-certified obesity medicine specialist and member of the HealthRX medical advisory board, describes the patient journey this way: "Most Arizona patients come in having already done significant research. Our job is to complete a thorough evaluation, order the right labs, and get the prescription moving quickly. The biggest delay we see is prior authorization, not the clinical evaluation itself."

The HealthRX team also advises Arizona patients on the 503A compounding option when brand-name supply is constrained or cost is prohibitive, taking into account the current FDA shortage designation for tirzepatide formulations.